Compare SLDP & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | FLGT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.8M | 867.4M |
| IPO Year | N/A | 2016 |
| Metric | SLDP | FLGT |
|---|---|---|
| Price | $3.82 | $24.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 4.7M | 175.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $4.33 | $16.84 |
| Revenue Next Year | $10.19 | $9.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $14.57 |
| 52 Week High | $8.86 | $31.04 |
| Indicator | SLDP | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 52.16 |
| Support Level | $3.87 | $21.97 |
| Resistance Level | $4.70 | $28.61 |
| Average True Range (ATR) | 0.20 | 0.72 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 75.68 | 99.18 |
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.